EyePoint Pharmaceuticals: Regulation Fd Disclosure

Item 7.01. Regulation FD Disclosure.On March 20, 2026, EyePoint, Inc. (the “Company”) filed a complaint against Ocular Therapeutix, Inc. (the “Defendant”) in the Middlesex County Superior Court for the Commonwealth of Massachusetts (the “Complaint”). The Complaint alleges, among other things, Defendant’s dissemination of false or misleading representations of fact concerning the Company and the clinical results of the Company’s lead product candidate, DURAVYU™ (vorolanib intravitreal insert). The Complaint asserts several causes of action against the Defendant, including defamation, commercial disparagement, violation of Mass. Gen. L. c. 93A, §§ 2 and 11, and tortious interference with advantageous business relations. The Company is seeking injunctive relief preventing Defendant from further disseminating the false or misleading representations of fact, requiring its public retraction of the false and misleading statements, monetary damages, attorneys’ fees and costs, and such other relief that the court deems just and proper.As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT, INC. Date: March 20, 2026 By: /s/ George O. Elston George O. ElstonExecutive Vice President and Chief Financial Officer

EyePoint Pharmaceuticals: Regulation Fd Disclosure

Şirketle ilgili diğer haberler